Lorus Therapeutics, Inc., a life sciences company, focuses on the discovery, research, and development of anticancer therapies in Canada. The company develops Virulizin, an immunotherapy agent for various cancer indications, including breast, ovarian, and pancreatic cancers. Virulizin also induces the expression of various cytokine proteins, such as IL-12 and IL-17E, which act as chemical messengers to boost the cellular immune response against cancer. The company's products also comprise LOR-2040, an RNA-targeting agent, which is in clinical development decreases expression of the R2 subunit of ribonucleotide reductase, in various clinical development stages for the treatment of renal cancer, leukemia, bladder cancer, and breast cancer; LOR-1284, a preclinical development stage product for several human tumor models, including renal cell carcinoma, melanoma, and colon adenocarcinoma; LOR-253 for non-small cell lung cancer, colon cancer, and leukemia; LOR-264, an orally active second-generation derivative of LOR-253; and LOR-220 that targets cancer specific genes comprising PI3K, which are critical in a signal pathway involved in tumorigenesis and malignancy. In addition, the company develops Interleukin-17E (IL-17E), a protein-based therapeutic. Lorus Therapeutics is headquartered in Toronto, Canada.
|
